Blood pressure reductions within 3-4 weeks in the home no drugs

Main Category: Hypertension
Article Date: 22 Apr 2004 - 0:00 PDT

email to a friend   printer friendly   opinions  

Non-drug treatment device delivers sustained blood pressure reductions within 3-4 weeks in the home.

New study published in American Journal of Hypertension further supports the device-guided-breathing-exercise treatment approach

High blood pressure was significantly decreased using a new non-drug treatment device, RESPeRATE®, according to a study published in this month's edition of the American Journal of Hypertension.

The controlled study of 79 patients performed at one of Europe's leading hypertension centers, Clinica Medica, Universita di Milano Bicocca and Ospedale San Gerardo in Monza, demonstrated that 15 minutes of daily self-treatment with the RESPeRATE® device significantly reduces home blood pressure in both medicated and non-medicated patients, and that the bulk of the reduction is achieved within 3-4 weeks.

The reductions were significantly greater than those observed in patients in the control group. Patients in both groups self-monitored their blood pressure with data-logging digital blood pressure monitors. The study also demonstrated quantitatively that patients displayed good compliance with RESPeRATE® treatment-- with many patients insisting on continuing the treatment after the trial ended.

"RESPeRATE has demonstrated significant antihypertensive effect in the home setting and high patient compliance," said Prof. Giuseppe Mancia, past president of the European Society of Hypertension, who led the study group with Prof. Cristina Giannattasio. "In fact, patients' satisfaction with this treatment enabled a 6-month follow up that demonstrated continued compliance and sustained lower blood pressure levels."

"We believe that these positive findings together with the successful results from the other 6 RESPeRATE clinical trials will expedite the integration of RESPeRATE into the standard of care for hypertension treatment," said Erez Gavish, President & CEO of InterCure, the developer of RESPeRATE. "In the US, thousands of patients and physicians have already incorporated RESPeRATE into their hypertension treatment and we hope that many more will do so by taking advantage of our newly created professional sampling program."

About InterCure Inc. and RESPeRATE®

InterCure (www.intercure.com) is a medical device company that creates and sells products that harness the therapeutic power of breathing for the treatment of hypertension, heart failure, respiratory diseases and other conditions. With 7 successful clinical trials, RESPeRATE® (www.resperate.com), InterCure's first product, became the only non-drug medical device indicated by the FDA for the adjunctive treatment of hypertension.

Contact: Tom Kirwan
tkirwan@intercure.com
347-528-7734
InterCure

• Additional
• References
• Citations